Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Related Keywords

Jamesl Gulley ,David Sallman ,Maryl Nora Disis ,Steven Harasym ,Helen Sabzevari ,Clintt Allen ,Uw Center ,Linkedin ,H Lee Moffitt Cancer Center Research Institute ,National Institutes Of Health ,University Of Washington Uw Professor Medicine ,Nasdaq ,Exchange Commission ,Oncology Service ,Department Of Malignant Hematology ,Clinical Research Division At Fred Hutch ,Precigen Inc ,Translational Medicine ,Clinical Research Division ,Fred Hutch ,Assistant Member ,Malignant Hematology ,Moffitt Cancer Center ,Research Institute ,Branch Chief ,Medical Oncology Service ,National Institutes ,Principal Investigator ,Translational Tumor Immunology ,Advancing Medicine ,Annual Report ,Precigen ,Nc ,